Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
It Was Your Biology
Why this matters for India: Generic entry could unlock a 5,000+ crore opportunity over the next 1215 months Prices may drop 3050% initially, and potentially 7075% over time #GLP-1 adoption in diabetes care is expected to rise sharply, adding 0.51% to IPM growth in FY27 Competition is intensifying, with 1015 players vying for share across India, regulated, and emerging markets Novo Nordisk has already launched Ozempic in India (Dec 2025), setting the stage for one of the most closely watched generic transitions in recent pharma history
H., Petrovic, A., & Seiwerth, S
More commonly, reported adverse gastrointestinal side effects resulted in hospitalization, with approximately 43% of patients reporting gastrointestinal issues related to semaglutide intake requiring hospitalization
The information provided on this blog is for general informational purposes only
